Ergomed plc Board and Management Changes (3757C)
April 13 2017 - 1:00AM
UK Regulatory
TIDMERGO
RNS Number : 3757C
Ergomed plc
13 April 2017
PRESS RELEASE
FOR IMMEDIATE RELEASE
Board and Management Changes
London, UK - 13 April 2017: Ergomed plc (LSE: ERGO) ('Ergomed'
or 'the Company'), a company dedicated to the provision of
specialised services to the pharmaceutical industry and the
development of new drugs, announces Board and management
changes.
Neil Clark will step down as a Director of Ergomed plc with
effect from 16 April 2017. Neil is leaving to become Chief
Executive Officer of Destiny Pharma Limited, a company focused on
the discovery, development and commercialisation of novel
antimicrobials. Neil will remain on the Board of our subsidiary,
PrimeVigilance, as a non-executive director and a consultant during
a transition period.
Dr. Jan Petracek will step into the role of Chief Executive
Officer of PrimeVigilance. Jan joined Ergomed in November 2016 as
CEO of European PharmInvent Services s.r.o. following its
acquisition and subsequent integration into PrimeVigilance.
Dr. Miroslav Reljanovic, Chief Executive Officer of Ergomed,
said:
"I would like to give my sincere thanks to Neil for his eight
years' service to Ergomed. He has helped the Company transition
from a private company through the IPO process in 2014 and
latterly, overseen a period of strong growth in PrimeVigilance. I
wish him all the best in the next stage of his career.
"We are fortunate to have in the wings a replacement CEO of the
calibre of Dr. Jan Petracek. As founder of PharmInvent and former
regulator at EMA, his unique combination of entrepreneurship and
specialist pharmacovigilance expertise will serve to drive forward
our pharmacoviglance businesses."
Enquiries:
Ergomed plc Tel: +44 (0) 1483
503205
Miroslav Reljanovic (Chief
Executive Officer)
Stephen Stamp (Chief Financial
Officer,)
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
Stifel Nicolaus Europe Limited Tel: +44 (0) 20
7710 7600
Jonathan Senior / Ben Maddison
(Joint Broker)
FTI Consulting - for UK enquiries Tel: +44 (0) 20
3727 1000
Simon Conway / Mo Noonan /
Natalie Garland-Collins
MC-Services - for Continental Tel: +49 211 52925222
European enquiries
Anne Hennecke
About Ergomed
Ergomed plc is a profitable UK-based business providing drug
development services to the pharmaceutical industry and has a
growing portfolio of co-development partnerships. It operates in
over 50 countries.
Ergomed provides clinical development, trial management and
pharmacovigilance services to over 100 clients ranging from top 10
pharmaceutical companies to small and mid-sized drug development
companies. Ergomed successfully manages clinical development from
Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular
expertise in oncology, neurology and immunology and the development
of orphan drugs. Ergomed believes its approach to clinical trials
is differentiated from that of other providers by its innovative
Study Site Management model and the use of Study Physician Teams,
resulting in a close relationship between Ergomed and the
physicians involved in clinical trials.
As well as providing high quality clinical development services,
Ergomed is building a portfolio of co-development partnerships with
pharma and biotech companies which share the risks and rewards of
drug development. Ergomed leverages its expertise and services in
return for carried interest in the drugs under development. Lastly,
Ergomed recently acquired a pipeline of proprietary development
products for haemostasis in surgical settings. For further
information, visit: http://ergomedplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEASLAFLLXEFF
(END) Dow Jones Newswires
April 13, 2017 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024